Methods and Treatment of Trauma Adverse Events with Oxygen Reduced Blood

Hemanext Inc.

A patent family: one line of work, grouped by real continuity rather than by a technology label inferred from titles. 7 of these applications claim priority to application PCT/US2018/033404, filed May 18, 2018. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.

Patent	Title	Holder	Status	Expires	Time remaining	Confidence
US 10,898,517	Methods and Treatment of Trauma Adverse Events with Oxygen Reduced Blood Hemanext Inc. In force Term ends May 18, 2038 · Medium confidence	Hemanext Inc.	In force	Term ends May 18, 2038	Term ends May 18, 2038	Medium confidence
US 11,026,970	Methods and Treatment of Trauma Adverse Events with Oxygen Reduced Blood Hemanext Inc. In force Term ends May 18, 2038 · High confidence	Hemanext Inc.	In force	Term ends May 18, 2038	Term ends May 18, 2038	High confidence
US 11,026,971	Methods and Treatment of Trauma Adverse Events with Oxygen Reduced Blood Hemanext Inc. In force Term ends May 18, 2038 · Low confidence	Hemanext Inc.	In force	Term ends May 18, 2038	Term ends May 18, 2038	Low confidence
US 11,033,581	Methods and Treatment of Trauma Adverse Events with Oxygen Reduced Blood Hemanext Inc. In force Term ends May 18, 2038 · Medium confidence	Hemanext Inc.	In force	Term ends May 18, 2038	Term ends May 18, 2038	Medium confidence
US 11,052,110	Methods and Treatment of Trauma Adverse Events with Oxygen Reduced Blood Hemanext Inc. In force Term ends May 18, 2038 · Low confidence	Hemanext Inc.	In force	Term ends May 18, 2038	Term ends May 18, 2038	Low confidence
US 12,582,674	Methods and Treatment of Trauma Hemanext Inc. In force Term ends May 18, 2038 · High confidence	Hemanext Inc.	In force	Term ends May 18, 2038	Term ends May 18, 2038	High confidence
US 11,576,931	Methods and Treatment of Trauma Adverse Events with Oxygen Reduced Blood Hemanext Inc. In force Term ends Sep 27, 2038 · Medium confidence	Hemanext Inc.	In force	Term ends Sep 27, 2038	Term ends Sep 27, 2038	Medium confidence
Application 19/541,026	Methods and Treatment of Trauma Hemanext Inc. Pending Not granted	Hemanext Inc.	Pending	Not granted	not computed

8 of 8 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.

7 of these are in force and held by Hemanext Inc..

Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know

Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.